WebElahere can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis. ... When a drug is being reviewed for coverage under a member’s medical benefit plan or is otherwise subject to clinical ... coverage or provider reimbursement policy. Please refer to the member's contract ... WebNov 14, 2024 · Patients received Elahere™ 6 mg/kg (based on adjusted ideal body weight) as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. Tumor response assessments occurred every 6 weeks for the first 36 weeks and every 12 weeks thereafter.
Oncology Medication Clinical Coverage
WebJan 18, 2024 · Elahere (mirvetuximab soravtansine-gynx) injection, for intravenous use is a prescription medicine used to treat symptoms of Ovarian Cancer. Elahere may be used alone or with other medications. Elahere belongs to a class of drugs called Antineoplastics, Monoclonal Antibody. It is not known if Elahere is safe and effective in children. WebELAHERE. ELAHERE. TM (mirvetuximab soravtansine-gynx) injection, for intravenous use Initial U.S. Approval: 2024 . WARNING: OCULAR TOXICITY . See full prescribing … theater at madison square garden nyc
Medicare Coverage - Lighthouse, An Alera Group Company
WebListing of a code in this policy does not imply that the service described by the code is a covered or non -covered health service. Benefit coverage for health services is … WebELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer responding to treatment with platinum-based chemotherapy and. have received 1 to 3 prior types of chemotherapy. WebElahere is 6 mg/kg adjusted ideal body weight administered once every 3 weeks (21-day cycle) as an intravenous (IV) infusion until disease progression or unacceptable toxicity. … the godfather house in ny